文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.

作者信息

Ichinohe Takeshi, Watanabe Izumi, Tao Eriko, Ito Satoshi, Kawaguchi Akira, Tamura Shin-ichi, Takahashi Hidehiro, Sawa Hirofumi, Moriyama Masami, Chiba Joe, Komase Katsuhiro, Suzuki Yujiro, Kurata Takeshi, Sata Tetsutaro, Hasegawa Hideki

机构信息

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

出版信息

J Med Virol. 2006 Jul;78(7):954-63. doi: 10.1002/jmv.20647.


DOI:10.1002/jmv.20647
PMID:16721854
Abstract

A safe and effective adjuvant is necessary to enhance mucosal immune responses for the development of an inactivated intranasal influenza vaccine. The present study demonstrated the effectiveness of surf clam microparticles (SMP) derived from natural surf clams as an adjuvant for an intranasal influenza vaccine. The adjuvant effect of SMP was examined when co-administered intranasally with inactivated A/PR8 (H1N1) influenza virus hemagglutinin vaccine in BALB/c mice. Administration of the vaccine with SMP induced a high anti-PR8 haemagglutinin (HA)-specific immunoglobulin A (IgA) response in the nasal wash and immunoglobulin G (IgG) response in the serum, resulting in protection against both nasal-restricted infection and lethal lung infection by A/PR8 virus. In addition, administration of SMP with A/Yamagata (H1N1), A/Beijing (H1N1), or A/Guizhou (H3N2) vaccine conferred complete protection against A/PR8 virus challenge in the nasal infection model, suggesting that SMP adjuvanted vaccine can confer cross-protection against variant influenza viruses. The use of SMP is suggested as a new safe and effective mucosal adjuvant for nasal vaccination against influenza virus infection.

摘要

相似文献

[1]
Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.

J Med Virol. 2006-7

[2]
Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

J Med Virol. 2010-1

[3]
Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.

J Med Virol. 2005-1

[4]
Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

J Virol. 2005-3

[5]
Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.

Vaccine. 2011-10-31

[6]
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Virology. 2008-10-25

[7]
Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.

Eur J Immunol. 1992-2

[8]
Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.

Eur J Immunol. 1991-6

[9]
Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.

J Immunol. 1992-8-1

[10]
Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.

Microbiol Immunol. 2008-2

引用本文的文献

[1]
Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses.

Vaccines (Basel). 2021-4-7

[2]
[Immunity and antiviral vaccinations. Example: the respiratory mucosa].

Antibiotiques (Paris). 2007-5

[3]
Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses.

Vet World. 2017-2

[4]
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Protein Cell. 2015-7

[5]
Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells.

Virol J. 2012-6-14

[6]
Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia.

PLoS One. 2012-1-27

[7]
Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

Ther Clin Risk Manag. 2009-3-26

[8]
Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus.

J Exp Med. 2008-12-22

[9]
Innate sensors of influenza virus: clues to developing better intranasal vaccines.

Expert Rev Vaccines. 2008-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索